2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

 

  • Ignatius, E. H., Abdelwahab, M. T., Hendricks, B., Gupte, N., Narunsky, K., Wiesner, L., Barnes, G., Dawson, R., Dooley, K. E., & Denti, P. (2020). Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrobial Agents and Chemotherapy, AAC.01196-20. https://doi.org/10.1128/AAC.01196-20
     
  • Nyberg, H. B., Draper, H. R., Garcia-Prats, A. J., Thee, S., Bekker, A., Zar, H. J., Hooker, A. C., Simon Schaaf, H., McIlleron, H., Hesseling, A. C., & Denti, P. (2020). Population pharmacokinetics and dosing of ethionamide in children with tuberculosis. Antimicrobial Agents and Chemotherapy, 64(3). https://doi.org/10.1128/AAC.01984-1
     
  • Abdelwahab, M. T., Leisegang, R., Dooley, K. E., Mathad, J. S., Wiesner, L., McIlleron, H., Martinson, N., Waja, Z., Letutu, M., Chaisson, R. E., & Denti, P. (2020). Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV. Antimicrobial Agents and Chemotherapy, 64(3), 1774–1780. https://doi.org/10.1128/AAC.01978-19
     
  • Abdelwahab, M. T., Wasserman, S., Brust, J. C. M., Gandhi, N. R., Meintjes, G., Everitt, D., Diacon, A., Dawson, R., Wiesner, L., Svensson, E. M., Maartens, G., & Denti, P. (2020). Clofazimine pharmacokinetics in patients with TB: Dosing implications. Journal of Antimicrobial Chemotherapy, 75(11), 3269–3277. https://doi.org/10.1093/jac/dkaa310
     
  • Wasmann, R. E., Svensson, E. M., Walker, A. S., Clements, M. N., & Denti, P. (2020). Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children. British Journal of Clinical Pharmacology, 1–8. https://doi.org/10.1111/bcp.14694
     
  • Schutz, C., Chirehwa, M., Barr, D., Ward, A., Janssen, S., Burton, R., Wilkinson, R. J., Shey, M., Wiesner, L., Denti, P., McIlleron, H., Maartens, G., & Meintjes, G. (2020). Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. British Journal of Clinical Pharmacology, 86(5), 966–978. https://doi.org/10.1111/BCP.14207
     
  • Nabisere, R., Musaazi, J., Denti, P., Aber, F., Lamorde, M., Dooley, K. E., Aarnoutse, R., Sloan, D. J., and Sekaggya-Wiltshire, C. (2020). Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials 21, 181 (2020). https://doi.org/10.1186/s13063-020-4132-7
     
  • Rabie, H., Tikiso, T., Lee, J., Fairlie, L., Strehlau, R., Bobat, R., Liberty, A., McIlleron, H., Andrieux-Meyer, I., Cotton, M., Lallemant, M., & Denti, P. (2020). Abacavir exposure in children cotreated for tuberculosis with rifampin and superboosted lopinavir-ritonavir. Antimicrobial Agents and Chemotherapy, 64(5). https://doi.org/10.1128/AAC.01923-19
     
  • Francis, J., Barnes, K. I., Workman, L., Kredo, T., Vestergaard, L. S., Hoglund, R. M., Byakika-Kibwika, P., Lamorde, M., Walimbwa, S. I., Chijioke-Nwauche, I., Sutherland, C. J., Merry, C., Scarsi, K. K., Nyagonde, N., Lemnge, M. M., Khoo, S. H., Bygbjerg, I. C., Parikh, S., Aweeka, F. T., … Denti, P. (2020). An individual participant data population pharmacokinetic meta-analysis of drug-drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrobial Agents and Chemotherapy, 64(5). https://doi.org/10.1128/AAC.02394-19

  • Chirehwa, M. T., Court, R., de Kock, M., Wiesner, L., de Vries, N., Harding, J., Gumbo, T., Maartens, G., Warren, R., Denti, P., & McIlleron, H. (2020). Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrobial Agents and Chemotherapy, 64(11). https://doi.org/10.1128/AAC.01381-20